A

ABC transporters, see ATP-binding cassette transporters
ABCG2
  structure, 280
  substrate specificity, 281
  tissue distribution, 281
Absolute recovery, calculation, 93
Accuracy, analyte assays, 103–105, 109
N-Acetyltransferase, drug metabolism, 203, 204
Albumin, see Plasma protein binding, anticancer drugs
Aldehyde dehydrogenase (ALDH)
  drug metabolism, 190, 191
  isoforms, 190
  polymorphisms, 191
Aldehyde oxidase, drug metabolism, 195
ALDH, see Aldehyde dehydrogenase
Allele, definition, 594
Allelic pair, definition, 594
Androgen receptors, anticancer drug targeting, 6, 7
Angiogenesis inhibitors evaluation with microdialysis, 317
anticancer targeting, 15, 16
combination radiation therapy
  angiotatin studies, 434
  endostatin studies, 434, 435
  local control of primary tumors, 434
  micrometastatic disease, 436
  prospects, 437
vascular endothelial growth factor inhibition, 435, 436
endothelium as target, 433
imaging of angiogenesis, 436
two-cell compartment model of tumors and rationale, 431, 432
Antibodies, see Immunotherapy
AP-1, anticancer drug targeting, 9, 10
Apoptosis, anticancer drug targeting, 14, 15
Area-under-the time–concentration curve (AUC)
  body size effects, 61, 62
determination, 60
starting dose considerations, 60
ATP-binding cassette (ABC) transporters, see also ABCG2; MRP drug transporters; P-glycoprotein
ABCA2 family members, 282
ABCB11, 281, 282
classification and types, 268, 269
drug resistance mechanisms, 267, 268
multidrug transporters, 271
structures, 268, 271
substrate specificities, 270, 282, 283
AUC, see Area-under-the time–concentration curve

B

BBB, see Blood–brain barrier
BCB, see Blood–cerebrospinal fluid barrier
Bcl-2, anticancer drug targeting, 15
Bcr-Abl, anticancer drug targeting, 8
Bioavailability, calculation, 133
Blood–brain barrier (BBB)
  anatomy, 374
  biochemical disruption for drug delivery, 384
  drug modification for permeability, 382
  hyperosmolar disruption for drug delivery, 383, 384
  paracellular diffusion, 374
  pharmacokinetics, 376, 377
  transcellular diffusion, 374
  transporters, 374, 375
Blood–cerebrospinal fluid barrier (BCB), characteristics, 376
Blood sampling, capillary vs venous sampling, 87, 88
Blood–tumor barrier (BTB)
  biochemical disruption for drug delivery, 384
  characteristics, 375, 376
Body surface area (BSA)
  definition, 58
  drug clearance correlations, 61, 62
  pediatric pharmacokinetics, 402, 403
  rationale for use in drug dose determination, 58
Brain tumors, see also Central nervous system blood–tumor barrier characteristics, 375, 376
drug delivery
  biochemical blood–brain barrier disruption, 384
  biodegradable polymer release, 386, 387
  convection-enhanced delivery, 387, 388
  drug modification for permeability, 382
evaluation, 381
factors affecting, 380, 381
high-dose systemic chemotherapy, 382
hyperosmolar blood–brain barrier disruption, 383, 384
intraarterial administration, 382, 383
intrathecal chemotherapy, see Intrathecal chemotherapy
intratumoral and intracavitary injection, 386
pharmacological principles, 381
receptor-mediated transport, 384
drug resistance mechanisms
  glutathione S-transferase protection, 378, 379
  O6-methylguanine-DNA methyltransferase protection, 379
MRPs, 378
organic anion transporters, 378
P-glycoprotein, 377, 378
therapeutic role of drug pumps, 378
topoisomerase II protection, 380
drug–drug interactions
  anticonvulsants, 389
  glucocorticoids, 389
epidemiology, 373
prognosis, 373
BSA, see Body surface area
BTB, see Blood–tumor barrier
Busulfan
  exposure–response relationship, 528
  intrathecal chemotherapy, 301, 302
C
Calibration, method validation, 94–97
Calibration curves, analyte assays, 84, 85
Cancer cells, characteristics, 1
Cancer vaccines, see Tumor vaccines
Carbonyl reductase, drug metabolism, 199, 200
Carboplatin, exposure–response relationship, 531
Cell cycle
  anticancer drug targeting, 12–14
  G1–S checkpoint, 12
  G2–M checkpoint, 12
  p53 regulation, 13
Central nervous system (CNS), see also Blood–brain barrier; Blood–tumor barrier
  anticancer drug penetration in systemic therapy, 292
  brain tumors, see Brain tumors
  intrathecal chemotherapy, see Intrathecal chemotherapy
microdialysis studies, see Microdialysis
Cerebrospinal fluid (CSF)
  blood barrier, see Blood–cerebrospinal fluid barrier
  flow effects in intrathecal chemotherapy, 296, 297
Chemical stability, see Stability, anticancer drugs
CHPP, see Continuous hyperthermic peritoneal perfusion
Chromatin regulation, anticancer drug targeting, 10, 11
Cisplatin
  assays, 85
  continuous hyperthermic peritoneal perfusion, 330, 331, 334
  isolated lung perfusion
    clinical trials, 354–356, 368
    pharmacokinetics, 364, 365
    stability studies, 82
Clinical trials, see also Phase I trials; Phase III trials
cancer drugs in development by trial phase, 539, 540, 583–585
design for drug approval
  analog evaluation and trial design, 590, 591
  clinical benefit as endpoint for drug approval, 589, 590
  overview, 581, 582, 591
  special designs
    patients as their own controls, 585–587
    randomized discontinuation trials, 588, 589
    randomized Phase II trial, 587, 588
drug attrition rates, 551, 555, 579, 580
investigational new drug application, 541
objectives and overview
  Phase I trials, 541, 542
  Phase II trials, 542, 543
  Phase III trials, 543
  Phase IV trials, 543, 544
prevalence in oncology, 540, 541
c-Myc, anticancer drug targeting, 10
CNS, see Central nervous system
Continuous hyperthermic peritoneal perfusion (CHPP)
  clinical trials, 334
  indications, 328
  limitations, 328, 329
  pharmacokinetics, 330–333
  rationale, 327
  technique, 329, 330
COX-2, see Cyclooxygenase-2
Creatinine clearance, calculation in elderly patients, 426
CSF, see Cerebrospinal fluid
Curcumin, chemoprevention, 18
Cyclooxygenase-2 (COX-2), chemoprevention, 18
Cyclophosphamide, pediatric pharmacokinetics, 406, 407
Cyclosporine, CYP3A4 activity modulation, 224
CYPs, see Cytochrome P450 enzymes
Cytochrome P450 enzymes
children, 399, 400
classification, 215
CYP2D6 and drug efficacy-predicting genotypes, 605, 606
CYP3A4
dose adaptation during protracted etoposide therapy, 225
induction, 223
modulation of activity
cyclosporine, 224
docetaxel, 224
etoposide, 224
ketooconazole, 224
paclitaxel, 224, 225
vaipodar, 224, 225
phenotyping, 223
polymorphisms, 222, 223
drug substrates and enzyme isoforms
overview, 218, 219
oxaphosphorine, 219, 220
tamoxifen, 220
tegafur, 219
thaiidomide, 221, 222
vinca alkaloids, 221
drug–drug interactions, see Drug–drug interactions
inducers, 217
inhibitors, 217
interindividual variations and dosing
considerations, 65, 125, 216, 217, 222, 601
nomenclature, 215, 216
polymorphisms, 217, 218
Cytosine arabinoside, intrathecal chemotherapy, 299

D
Death receptors, anticancer drug targeting, 14, 15
Delayed-type hypersensitivity (DTH), tumor vaccine evaluation, 464
Dendritic cell vaccines
clinical trials, 462
principles, 460
Detectability, analyte assays, 99, 101–103
Dihydrofolate reductase, anticancer drug targeting, 5
Dihydropyrimidine dehydrogenase (DPD)
drug metabolism, 195–197
drug toxicity-predicting genotypes, 604
inhibitors with 5-fluorouracil therapy, 196, 197
interindividual variations and dosing
considerations, 65
polymorphisms, 196, 233, 234
tissue distribution, 196
DNA methyltransferase, anticancer drug targeting, 10, 11
DNA, anticancer drug targeting
base pairs, 4
dihydrofolate reductase, 5
purine and pyrimidine incorporation, 4, 5
thymidylate synthase, 5
topoissomerases, 5, 6
DNA repair, polymorphisms in enzymes, 235–238
Docetaxel
CYP3A4 activity modulation, 224
exposure–response relationship, 530, 531
Dosing, see Starting dose
Doxorubicin
assays, 85, 86
blood sampling, capillary vs venous sampling, 87
isolated lung perfusion
clinical trials, 353, 354, 368, 369
pharmacokinetics, 365–367
stability studies, 82
DPD, see Dihydropyrimidine dehydrogenase
Drug–drug interactions
alternate mechanisms
liposome formulations, 256
regimen effects, 256, 257
vehicle effects, 255, 256
anticonvulsants, 389
clinical significance, 245, 246
direct interactions, 249
exploitation
oral delivery, 257
systemic administration, 257–259
glucocorticoids, 389
nonspecific effects, 249
pharmacokinetic processes in interactions
absorption, 246, 247
excretion
biliary, 253
renal, 253
metabolism
alkylation of enzymes, 251
competitive inhibition, 249, 250
down-regulation of enzymes, 251, 252
induction of enzymes, 252
overview, 247
suicide inhibition, 250, 251
transport, 247, 248
plasma protein binding role, 248, 249
prediction
analog data, 254
clinical studies, 255
in silico experiments, 254
in vitro experiments, 254
preclinical studies, 254, 255
prospects for study, 259
warfarin, 257
Drug resistance, see ATP-binding cassette transporters; ABCG2; MRP drug transporters; P-glycoprotein

Drug screening

cell-based screening assays
biochemical screening assays, 35, 36
combination of target and cell screens, 36, 37
monolayer culture assays, 34
MTT assay, 33
National Cancer Institute screen, 30–33
sulforhodamine B assay, 33
tailored screens, 34, 35
clinical predictivity of screening data
colony-forming assay, 41
hollow-fiber assay, 41
xenografts, 40–42
high-throughput screening capacity, 32
historical perspective, 30
model organisms, 37–40
rationale, 29

Drug tolerance models, pharmacometrics, 155–158
DTÇ101, intrathecal chemotherapy, 299, 300
DT-diaphorase (NQO1)
drug metabolism, 200, 201
polymorphisms, 601, 602

DTH, see Delayed-type hypersensitivity

E
EC₅₀, definition, 117, 118
Elderly patient pharmacokinetics
absorption and bioavailability, 423, 424
adverse drug reactions, 422
chemotherapeutic agent examples, 426–429
cross-sectional studies, 422, 423
definition of the elderly, 421, 422
distribution, 424
hepatic metabolism, 424, 425
renal excretion, 425, 426
ELISA, see Enzyme-linked immunosorbent assay
ELISPOT, see Enzyme-linked immunospot assay
Eₘₐₓ, model
overview, 117, 118, 145
pharmacometrics, 153, 154

Enzyme-linked immunosorbent assay (ELISA)
tumor vaccine evaluation, 465
Enzyme-linked immunospot assay (ELISPOT),
tumor vaccine evaluation, 465, 466
Epirubicin, assays, 86, 87
Epoxide hydrolase, drug metabolism, 199
Equipoise, definition, 547, 548
ERCC1, polymorphisms, 235–237
ERCC2, polymorphisms, 237
Erythropoietin
antigenicity, 512
pharmacokinetics, 502–504
Esterases, drug metabolism, 201
Estrogen receptors, anticancer drug targeting, 6
Etoposide
CYP3A4 activity modulation, 224
dose adaptation during protracted therapy, 225
pediatric pharmacokinetics, 408, 409
Exposure–response relationship
examples in drug development
busulfan, 528
carboplatin, 531
docetaxel, 530, 531
imatinib, 529, 530
zolendronic acid, 528
exposure variables, 525, 526
failure reasons in clinical trials, 524
labeling information, 532, 533
maximum tolerated dose concept, 523, 524
regulatory issues and guidance, 523, 524, 531, 532, 534
response variables
biomarkers, 526, 527
clinical endpoints, 527
surrogate endpoints, 527

F
5-Fluorouracil
dihydroxyuridine dehydrogenase
inhibitors with therapy, 196, 197
metabolism, 195, 196
polymorphisms in metabolizing enzymes, 232–234
5-Fluorouridine, isolated lung perfusion, 365

G
G-CSF, see Granulocyte colony-stimulating factor
Gemcitabine, intrathecal chemotherapy, 302
Gene therapy
gene transfer
nonviral gene transfer, 441, 442
strategies, 440
viral gene transfer, 442–446
herpes simplex virus suicidal transgene
adenoviral vector advantages and limitations, 448, 449
bystander effect, 447, 448
failure analysis, 451
principles, 446, 447
retroviral vector advantages and limitations, 449–451
historical perspective, 439, 440
mouse models and clinical utility, 451, 452
Phase III trials in cancer, 446–448

Genetic testing
American Society of Clinical Oncology guidelines
categories of testing, 602, 603
criteria for testing, 602
disease mutations vs drug response genetics, 593, 594
gene mutations in cancer
chromosomal rearrangements and leukemia, 598–600
oncogenes, 600, 601
point mutations in solid tumors, 600
tumor suppressor genes, 601
Mendelian genetics
definitions, 594
dominant inheritance, 595
recessive inheritance, 595
sex-linked disorders, 595, 597
single nucleotide polymorphisms, 597, 598
pedigree symbols, 594
pharmacogenetic counseling
benefits, 608
candidates for testing, 607, 608
confidentiality, 609
informed consent, 609
inheritance mode, 608
risks, 608
test considerations, 606, 607
testing conditions, 608
pharmacogenetics
drug toxicity-predicting genotypes
dihydropyrimidine dehydrogenase, 604
methyleneetahydrofolate reductase, 605
thiopurine methyltransferase, 604
UDP-glucuronosyltransferase, 604
drug efficacy-predicting genotypes
CYP2D6, 605, 606
thymidylate synthase, 605
topoisomerase I, 606
Genotype, definition, 594
Glucocorticoid receptors, anticancer drug targeting, 7
Glutathione S-transferase (GST)
brain tumor drug resistance role, 378, 379
drug metabolism, 202, 203
polymorphisms, 237, 238
GM-CSF, see Granulocyte-macrophage colony-stimulating factor
Granulocyte colony-stimulating factor (G-CSF), pharmacokinetics, 505–508
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
antigenicity, 512, 513
pharmacokinetics, 508–510
GST, see Glutathione S-transferase
H
Half-life, equations, 123, 132
Heat shock protein 90 (HSP90), anticancer drug targeting, 12
Hepatic elimination, interindividual variations and dosing considerations, 64
Heterozygote, definition, 594
High-throughput screening, see Drug screening
Hill coefficient, definition, 118
Hill model, see $E_{\text{max}}$ model
Histone acetylases, anticancer drug targeting, 11
Histone deacetylases, anticancer drug targeting, 11
Hollow-fiber assay
drug screening, 41
preclinical studies in mouse, 53, 54
Homozygote, definition, 594
HSP90, see Heat shock protein 90
I
Ideal body weight, drug dosing considerations, 59
Ifosfamide, pediatric pharmacokinetics, 406, 407
IHP, see Isolated hepatic perfusion
IL-2, see Interleukin-2
IL-12, see Interleukin-12
ILP, see Isolated limb perfusion
ILuP, see Isolated lung perfusion
Imatinib, exposure–response relationship, 529, 530
Immunotherapy
immunoglobulin G
FcRn interaction site localization, 483, 484
mutant studies of amino acid residues in catabolism
human, 481, 482
mouse, 479–481
mouse vs human, 482
persistence mechanisms in circulation, 477, 478
pharmacokinetic alterations in disease myotonic dystrophy, 491
overview, 490, 491
rheumatoid arthritis, 492
systemic lupus erythematosus, 491, 492
intravenous immunoglobulin pharmacokinetics, 490
monoclonal antibodies
antigenicity, 513, 514
attrition rates in clinical trials, 580, 581
elimination, 475, 476
human–mouse chimeras, 475, 476
immunotoxin preparation, 476
pharmacokinetics in humans
immunotoxin persistence in cancer patients, 488, 489
persistence in cancer patients, 488
pharmacokinetics in mice
immunotoxin persistence in normal and tumor-bearing mice, 484, 485
types in cancer treatment, 513, 514
prospects, 492, 493

Immunotoxins, see Immunotherapy

Interferons
antigenicity, 512
pharmacokinetics, 499–502

Interleukin-2 (IL-2)
antigenicity, 513
pharmacokinetics, 510

Interleukin-12 (IL-12), pharmacokinetics, 510–512

Intrathecal chemotherapy
busulfan, 301, 302
cytosine arabinoside, 299
delivery, 293, 294
dosing schedule, 294
DTC101, 299, 300
factors affecting drug exposure and distribution
age of patient, 296
cerebrospinal fluid flow, 296, 297
patient position, 297
gemcitabine, 302
mafosfamide, 301
methotrexate
intralumbar administration pharmacology, 297, 298
toxicity, 298, 299
principles, 385, 386
rationale, 289–291
systemic chemotherapy comparison, 291–293
thiotepa, 300
topotecan, 301

Intravenous immunoglobulin (IVIG), pharmacokinetics, 490

Intraventricular chemotherapy, principles, 385, 386

Irinotecan
pediatric pharmacokinetics, 410–412
polymorphisms in metabolizing enzymes, 234, 235

Isolated hepatic perfusion (IHP)
clinical trials, 337–340
indications, 335
pharmacokinetics, 337
rationale, 327, 328
technique, 335–337

Isolated limb perfusion (ILP)
clinical trials, 343, 344
indications, 335
pharmacokinetics, 342
rationale, 327, 328
technique, 340, 342

Isolated lung perfusion (ILuP)
advantages and limitations, 360, 370
clinical trials in lung cancer
cisplatin, 354–356, 368
doxorubicin, 353, 354, 368, 369
melphalan, 350, 351, 353
nitrogen mustard, 350, 351
paclitaxel, 356–359
table, 352
tumor necrosis factor-α, 356
complications, 360
drug penetration in tumor tissue, 369, 370
pharmacokinetic studies
cisplatin, 364, 365
doxorubicin, 365–367
5-fluorouridine, 365
melphalan, 367
paclitaxel, 367, 368
rationale, 363

IVIG, see Intravenous immunoglobulin

K
Ketoconazole, CYP3A4 activity modulation, 224

L
Lean body mass, drug dosing considerations, 58, 59
Leukemia, chromosomal rearrangements, 598–600
Limit of quantification (LOQ), analyte assays, 83, 84
Limiting dilution assay, tumor vaccine evaluation, 464

Liposomal anticancer agents
drug–drug interactions, 256
microdialysis in preclinical evaluation, 317, 318

LLOD, see Lower limit of detection

LLOQ, estimation, 102, 103

LOQ, see Limit of quantification

Lower limit of detection (LLOD), calculation, 102

Lung cancer
drug delivery, see Isolated lung perfusion
epidemiology, 349
metastases, 349, 350
pulmonary system anatomy, 350, 364
Index 619

M

Mafosfamide, intrathecal chemotherapy, 301
Magnetic resonance imaging (MRI)
  blood–tumor barrier, 375
  drug disposition in tumors and tissue, 308
MDR1, see P-glycoprotein
Mean residence time (MRT), calculation, 133
Melanoma, isolated limb perfusion trials, 343, 344
Melphalan, isolated lung perfusion
  clinical trials, 350, 351, 353
  pharmacokinetics, 367
6-Mercaptopurine, thiopurine methyltransferase
  metabolism, 197–199
Metabolism, anticancer drugs, see also Pharmacokinetics;
  specific enzymes
  clinical significance, 189, 190
  enzyme classification, 204, 205
  phase I vs phase II reactions, 189
  plasma protein binding effects, 180
Metastasis
  anticancer drug targeting, 17
  cell adhesion, 17
  cell invasion, 17
Methotrexate
  intrathecal chemotherapy
    intralumbar administration pharmacology, 297, 298
    toxicity, 298, 299
  pediatric pharmacokinetics, 404–406
Methylenetetrahydrofolate reductase (MTFR),
  drug toxicity-predicting genotypes, 605
O6-Methylguanine-DNA methyltransferase
  (MGMT), brain tumor drug resistance role, 379
MGMT, see O6-Methylguanine-DNA methytransferase
Microdialysis
  advantages, 309, 310
  calibration
    in vitro, 310, 311
    in vivo, 311, 312
  clinical studies
    tissue drug distribution, 319
  tumor drug distribution, 319, 320
  online real-time analysis, 312, 313
  pharmacodynamic studies
    antibiotics, 320, 321
    brain neurochemistry, 321, 322
  preclinical studies
    angiogenesis inhibitor evaluation, 317
    brain pharmacokinetic studies in nonhuman primates, 318
    liposomal anticancer agent evaluation, 317, 318
  tumor and tissue drug distribution, 313, 315–317
  principles, 308, 309
  prospects, 322, 323
  solid tumor drug delivery issues, 307, 308
  study design, 311
  system components and setup, 310
  Microtubules, anticancer drug targeting, 6
  Mitogen-activated protein kinase, anticancer
drug targeting, 8, 9
  Mitomycin C, continuous hyperthermic peritoneal
  perfusion, 333, 334
  Monoclonal antibodies, see Immunotherapy
Mouse models
  cautions in use, 51, 52
  clinical predictivity, 50, 51
  drug efficacy parameters, 48, 49
  drug screening, see Drug screening
  experimental design considerations, 46–48
  hollow-fiber assay, 53, 54
  increased lifespan calculation, 49
  National Cancer Institute xenograft protocol, 49, 50
  preclinical study goals, 45, 46
  transgenic and knockout mouse studies, 52, 53
  tumor weight calculation, 48
MRT, see Mean residence time
MTFR, see Methylenetetrahydrofolate reductase
m-TOR, anticancer drug targeting, 9
N
Nitrogen mustard, isolated lung perfusion, 350, 351
NQO1, see DT-diaphorase
Nuclear factor-κB, anticancer drug targeting, 10
O
Oxaphosphorine, cytochrome P450 metabolism, 219, 220
P
p53, mutation in cancer and restoration, 13–15
Paclitaxel
  CYP3A4 activity modulation, 224, 225
  isolated lung perfusion
    clinical trials, 356–359
    pharmacokinetics, 367, 368
  Pediatric pharmacokinetics
    absorption, 396–398
Index

clinical studies
  inadequacy of adult clinical trials, 395
  practical issues, 403, 404
  cyclophosphamide, 406, 407
distribution, 398, 399
dosing of anticancer drugs, 402, 403
etoposide, 408, 409
ifosfamide, 406, 407
irinotecan, 410–412
metabolism, 399, 400
methotrexate, 404–406
overview, 395, 396
prospects for study,
  renal excretion, 400–402
temozolomide, 412
vinblastine, 407, 408
PET, see Positron emission tomography
P-glycoprotein
  brain tumor drug resistance role, 377, 378
drug resistance mechanisms, 18
  clinical trials
    surrogate endpoints, 277, 279
table, 275
  first generation, 273, 274
  second generation, 274, 276, 277
  third generation, 277
interindividual variations and dosing considerations, 64, 125
physiological functions, 272, 273
polymorphisms, 234
structure, 271
substrates, 271
tumor expression, 273
PHARKNOWDISC, see Pharmacometric knowledge-based drug discovery
Pharmacodynamic modeling
  clinical settings, 140
data interpretation, 146, 147
determinants of pharmacodynamic effects, 140
  $E_{\text{max}}$ model, 117, 118, 145
implementation and assessment, 146
importance, 139, 140
pharmacometrics, see Pharmacometric knowledge-based drug discovery; Pharmacometrics
prospects, 147
sampling and measurement issues, 140, 141, 146
segregation analysis, 143, 144
toxicity measures and endpoints, 141, 142
Pharmacodynamics
  definition, 111, 139
drug action, 113, 114
enzyme inhibition, 113, 117
interindividual variability, 125, 126
non-receptor-mediated drug action, 117
pharmacokinetic relationship, 125
receptor pharmacology and function
  agonists, 115
  competitive antagonists, 116
  overview, 114, 115
  partial agonists, 117
tumor vaccines, see Tumor vaccines
Pharmacogenetic counseling, see Genetic testing
Pharmacokinetic modeling
  compartmental analysis, 130–134
metabolite kinetics, 135, 136
noncompartmental modeling, 124, 130
nonlinear dose-dependent pharmacokinetics, 124, 134
parameter estimation and model assessment, 134, 135
pharmacometrics, see Pharmacometric knowledge-based drug discovery; Pharmacometrics
sampling strategies, 129, 130, 136, 137
Pharmacokinetics
  absorption, 118–120
  blood–brain barrier crossing, 376, 377
children, see Pediatric pharmacokinetics
continuous hyperthermic peritoneal perfusion, 330–333
correlation with toxicity and tumor response, 60
cytokines
  erythropoietin, 502–504
  granulocyte colony-stimulating factor, 505–508
  granulocyte-macrophage colony-stimulating factor, 508–510
  interferons, 499–502
  interleukin-2, 510
  interleukin-12, 510–512
definition, 111, 129
distribution, 120
elderly patients, see Elderly patient pharmacokinetics
excretion, 121
immunoglobulins and immunotoxins, see Immunotherapy
interindividual variability, 125, 126
isolated hepatic perfusion, 337
isolated limb perfusion, 342
isolated lung perfusion, see Isolated lung perfusion
metabolism, 120, 121
parameters
  clearance, 122
  half-life of elimination, 123
volume of distribution, 121, 122
pharmacodynamic relationship, 125
population pharmacokinetics, 124, 125
Pharmacometric knowledge-based drug discovery (PHARKNOWDISC)
correct–learn approach to drug development, 151, 152
cost implications, 149
data sources, 149, 150
steps, 150, 151
Pharmacometrics
definition, 152
dose ranging trials, 161–163
drug tolerance models, 155–158
model applications, 163–165
Monte Carlo simulations, 160, 161
outcomes models, 158, 159
pharmacodynamic models, 152–154
pharmacokinetic models, 152
planning importance, 160
population models, 159, 160
real-time modeling, 160
Phase I trials
dose escalation, 77, 78
endpoints, 76, 78
limitations, 79, 80
objectives and overview, 541, 542
patient selection, 76
pharmacodynamic modeling, see Pharmacodynamic modeling
schedule selection, 77
starting dose selection, see Starting dose surrogate endpoints, 78, 79
Phase III trials
advantages and limitations, 556, 557
alternatives
adjustment techniques, 547
historical controls, 546, 547
sequential techniques, 547
costs, 549
decision model, factors for starting trial activity and toxicity in Phase I and Phase II testing
clinical benefit, 571
pharmacodynamic and therapeutic effects, 564, 565
randomized Phase II trials, 570
response rates, 565–567
therapeutic ratio, 567–570
time-to-progression in Phase II trial, 570, 571
factor analysis for Tarceva and Genasense, 573
mechanism of action, 558–561
overview, 556–558
pharmacokinetic properties in Phase I and Phase II testing, 563, 564
potential for market niche and strategic role for sponsor, 572
potential role in disease treatment, 571, 572
preclinical activity, 562, 563
duration, 550
financial effects on health care system, 550
Food and Drug Administration approval times and regulatory issues, 551–554
gene therapy trials in cancer, 446–448
historical perspective, 545
objectives and overview, 543
physician–patient relationship impact, 548, 549
randomization
advantages, 544, 545
ethical considerations and equipoise concept, 547, 548
sponsor type effects on goals, 556
success rates, 555
Phenotype, definition, 594
Phosphatidylinositol 3-kinase, anticancer drug targeting, 9
Plasma protein binding, anticancer drugs
assays
novel approaches, 172, 173
overview, 171, 172
separation methods, 172
spectroscopic methods, 172
association constant determination, 170, 171
clinical importance, 169, 170, 180–182
drug formulation interference, 179, 180
drug–drug interaction role, 248, 249
fraction of bound drug, 170
interindividial variability, 173, 174
irreversible binding, 178
metabolic interconversion effects, 180
protein concentration-dependent binding, 176, 177
protein types in plasma, 174–176
table of drugs, 177
Positron emission tomography (PET), drug disposition in tumors and tissue, 308
Precision, analyte assays, 103–105, 109
Proteasomes, anticancer drug targeting, 11, 12
Protein–drug interactions, see Plasma protein binding, anticancer drugs
Q
Quality control, bioanalytical methods, 106–109
R
Radiotherapy
combination angiogenesis inhibitor therapy
  angiostatin studies, 434
  endostatin studies, 434, 435
  local control of primary tumors, 434
  micrometastatic disease, 436
  prospects, 437
  vascular endothelial growth factor inhibition, 435, 436
  mechanisms of action, 432, 433
Rational drug design
  pharmacokinetic and pharmacodynamic considerations, 3
  target identification and validation, 2
Receptors, see also specific receptors
  agonists, 113, 115, 117
  antagonists, 113, 116
  pharmacology and function, see Pharmacodynamics
  signal transduction, anticancer drug targeting, 8
  targeting in cancer therapy, 3
Renal excretion
  drug–drug interactions, 253
  elderly patient pharmacokinetics, 425, 426
  pediatric pharmacokinetic evaluation, 400–402
Retinoic acid receptors
  anticancer drug targeting, 7
  chemoprevention, 17, 18
RMP-7, blood–brain barrier disruption for drug delivery, 384
S
Sarcoma, isolated limb perfusion trials, 343, 344
Screening, see Drug screening
Selectivity, analyte assays, 83, 97–99
Signal transduction, anticancer drug targeting
  Bcr-Abl, 8
  m-TOR, 9
  mitogen-activated protein kinase pathway, 8, 9
  phosphatidylinositol 3-kinase, 9
  receptors, 8
  Src, 8
  STAT, 9
Single nucleotide polymorphisms (SNPs), see also specific genes
  definition, 597
  haplotypes, 597, 598
SNPs, see Single nucleotide polymorphisms
Src, anticancer drug targeting, 8
Stability, anticancer drugs
  biological material studies
    alkylating agents, 82
    anthraquinone glycosides, 82
    cisplatin, 82
  storage, 82, 83
testing in method validation, 105, 106
Starting dose
  body surface area
    definition, 58
  drug clearance correlations, 61, 62
  rationale for use in dose determination, 58
  fixed dose advantages and disadvantages, 66, 67
  ideal body weight considerations, 59
  interindividual variations
    cytochrome P450 enzymes, 65
    dihydropyrimidine dehydrogenase, 65
    hepatic elimination, 64
    P-glycoprotein, 64
  lean body mass considerations, 58, 59
  pharmacokinetic correlation with toxicity and tumor response, 60
Phase I trials, 76, 77
  schema in new drug development, 68, 69
  targeted therapies, 66
  toxicity-adjusted doses, 67
  underdosing dangers, 62, 63
  volume of distribution and clearance considerations, 59, 60
STAT, anticancer drug targeting, 9
Sulfotransferases, drug metabolism, 202
T
Tamoxifen, cytochrome P450 metabolism, 220
Tegafur, cytochrome P450 metabolism, 219
Telomerase, anticancer drug targeting, 15
Temozolomide, pediatric pharmacokinetics, 412
Thalidomide, cytochrome P450 metabolism, 221, 222
6-Thioguanine, thiopurine methyltransferase metabolism, 197–199
Thiopurine methyltransferase (TPMT)
  drug metabolism, 197–199
  drug toxicity-predicting genotypes, 604
  polymorphisms, 198
  tissue distribution, 197, 198
Thiotepa, intrathecal chemotherapy, 300
Thymidylate synthase
  anticancer drug targeting, 5
  drug efficacy-predicting genotypes, 605
  herpes simplex virus suicidal transgene in gene therapy
  adenoviral vector advantages and limitations, 448, 449
  bystander effect, 447, 448
  failure analysis, 451
  principles, 446, 447
  retroviral vector advantages and limitations, 449–451
  mouse models and clinical utility, 451, 452
  polymorphisms, 232, 233, 240
Index

TNF-α, see Tumor necrosis factor-α

Topoisomerase I
  anticancer drug targeting, 5, 6
  drug efficacy-predicting genotypes, 606

Topoisomerase II
  anticancer drug targeting, 5, 6
  brain tumor drug resistance role, 380

Topotecan
  intrathecal chemotherapy, 301
  pediatric pharmacokinetics, 409, 410

TPMT, see Thiopurine methyltransferase

Transcription factors, anticancer drug targeting
  AP-1, 9, 10
  c-Myc, 10
  nuclear factor-κB, 10

Tumor necrosis factor-α (TNF-α)
  continuous hyperthermic peritoneal perfusion, 330, 331
  isolated hepatic perfusion, 340
  isolated limb perfusion, 343
  isolated lung perfusion, 356

Tumor vaccines
  administration schedules, 466–468
  clinical trial regulatory issues, 468, 469
  combination therapies, 468
  pharmacodynamics and immunological endpoints
    delayed-type hypersensitivity, 464
    enzyme-linked immunosorbent assay, 465
    enzyme-linked immunospot assay, 465, 466
    limiting dilution assay, 464
    overview, 463, 464
    tetramer assay, 465
  tumor-associated antigen vaccines
    advantages, 460, 461
    vectors
      replication competent vectors, 461, 463
      replication-defective vectors, 463
      viral vectors, 461
  whole tumor vaccines
    advantages, 459
    clinical trials, 457–459
    dendritic cell vaccines, 460, 462

  hybrid cell fusion, 459, 460

U

UDP-glucuronosyltransferase
  drug metabolism, 201, 202
  drug toxicity-predicting genotypes, 604
  interindividual variability, 216
  polymorphisms, 234

V

Vaccines, see Tumor vaccines

Vaispodar, CYP3A4 activity modulation, 224, 225

Validation, bioanalytical methods
  accuracy and precision, 103–105
  calibration, 94–97
  detectability, 99, 101–103
  method development, 93, 94
  overview, 91, 92
  selectivity of analyte assays, 83, 97–99
  stability testing, see Stability, anticancer drugs

Vascular endothelial growth factor (VEGF)
  anticancer drug targeting, 15, 16
  inhibition with combination radiation therapy, 435, 436

Vascular isolation and perfusion, see Isolated hepatic perfusion; Isolated limb perfusion

VEGF, see Vascular endothelial growth factor

Vinca alkaloids, cytochrome P450 metabolism, 221

Vincristine, pediatric pharmacokinetics, 407, 408

Volume of distribution
  modeling, 131, 133
  pharmacokinetics, 121, 122
  starting dose considerations, 59, 60

X

Xanthine oxidoreductase (XOR), drug metabolism, 192, 194

XOR, see Xanthine oxidoreductase

Z

Zolendronic acid, exposure–response relationship, 528